Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAB Trial of tozorakimab in COPD
ISRCTN35638452Phase 2Recruiting
- Sponsor
- University of Leicester
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tozorakimab with Placebo (2 arms). Primary endpoints: Improvement in semi-quantitative epithelial remodelling histology score and Improvement in granulocytic inflammation in the bronchial submucosa. Started Jun 2026; status: recruiting.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN35638452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN35638452.